Get the Stockscreener App
75.40
0.85%
-0.77
Ptc Therapeutics Inc stock is traded at $75.40, with a volume of 309.27K.
It is down -0.85% in the last 24 hours and down -2.80% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$76.17
Open:
$75.44
24h Volume:
309.27K
Relative Volume:
0.20
Market Cap:
$6.05B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-12.69
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+4.20%
1M Performance:
-2.80%
6M Performance:
+60.42%
1Y Performance:
+63.55%
1-Day Range:
$74.05
$77.55
1-Week Range:
$69.81
$77.55
52-Week Range:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
75.41 | 6.12B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Insider Monkey
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
A Look At PTC Therapeutics (PTCT) Valuation As 2026 Revenue Guidance Reshapes Market Expectations - Sahm
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
PTC Therapeutics reports $92.5M in Q4 Sephience revenue - Investing.com
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
PTC Therapeutics Reports Preliminary 2025 Product Revenue, Sets 2026 Product Revenue Guidance - marketscreener.com
Ptc Therapeutics provides update at J.P. Morgan annual healthcare conference - marketscreener.com
Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference - TradingView — Track All Markets
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - Yahoo Finance
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate - Chartmill
PTC Therapeutics, Inc. $PTCT Shares Purchased by SG Americas Securities LLC - MarketBeat
Market Outlook: Will PTC Therapeutics Inc stock sustain high P E ratios2025 EndofYear Setup & Expert Approved Trade Ideas - moha.gov.vn
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup - Chartmill
Is PTC Therapeutics Inc. stock a safe haven assetEarnings Risk Report & Growth Focused Stock Pick Reports - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $49,742.16 in Stock - MarketBeat
Neil Gregory Almstead Sells 1,026 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 3,016 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,279 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells $95,650.75 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 4,879 Shares of Stock - MarketBeat
Stop Loss: Is GDRX stock vulnerable to regulatory risksBuy Signal & Daily Momentum Trading Reports - moha.gov.vn
PTC Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
What dividend safety score for PTC Therapeutics Inc. stockQuarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating - marketscreener.com
PTC THERAPEUTICS, INC. (PTCT) - MSN
Lee Scott Golden Sells 1,340 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
How Royalty Sale, Sephience Approval and CEO Share Sale At PTC Therapeutics (PTCT) Has Changed Its Investment Story - Sahm
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):